



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area  
Dehradun, Uttarakhand 248 110, India  
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,  
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India  
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

April 2, 2024

To  
Listing / Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai – 400 001

To  
Listing / Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**BSE CODE: 543329**

**NSE SYMBOL: WINDLAS**

Dear Sir/ Madam.

**Sub: Press Release**

Please find attached herewith press release on “Windlas Biotech Limited commissions its State-of-the-Art Injectable Facility”.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**For Windlas Biotech Limited**

Ananta Narayan Panda  
**Company Secretary & Compliance Officer**

**Encl:** as above

## Press Release

### **Windlas Biotech Limited commissions its State-of-the-Art Injectable facility**

**Tuesday, 2<sup>nd</sup> April 2024, Gurugram:** Windlas Biotech Limited is pleased to announce the commissioning of its state-of-the-art injectable facility for manufacturing of Small Volume Parenteral products, built to meet international cGMP standards.

The Company has received manufacturing license from the Drug Controlling & Licensing Authority of Uttarakhand after joint inspection conducted by Central Drugs Standard Control Organisation and State Licensing Authority of Uttarakhand. The facility has initiated manufacturing of commercial batches and we expect to introduce several new products over the course of Financial Year 2025.

This milestone marks company's continued foray in development and manufacturing of complex dosage forms like Ampoules, Liquid Vials and Lyophilized Vials thereby extending its product portfolio to critical care and other specialized therapeutic segments. This Injectable plant shall cater to all three of our business verticals: CDMO, Trade Generics & Institutional, and Exports.

**Commenting on this achievement, Mr. Hitesh Windlass, Managing Director, Windlas Biotech** said, *"The commissioning of our injectable facility is a landmark event for us, signifying our dedication to bringing advanced and life-saving treatments to the market. This facility not only enhances our manufacturing capabilities across a new dosage format, but also demonstrates our commitment to excellence and innovation in pharmaceutical manufacturing. We are poised to meet the evolving demands of our valued customers and solidify our position as one of the frontrunners in the industry. We remain dedicated to upholding the high standards of quality, compliance, and customer satisfaction as we continue to drive innovation and growth in the pharmaceutical landscape."*

## **About Windlas Biotech Limited**

The company (Windlas) is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, the Company excels in developing its own product, process and regulatory intellectual property and provides its customers a comprehensive range of branded products for marketing in the domestic generic pharmaceutical industry. The company also markets a wide variety of its own branded Trade Generics & Institutional products across India. It is a growing exporter of various medical and nutraceutical products.

## **Safe Harbor**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

**For more information please contact:**



### **Windlas Biotech Limited**

CIN: U74899UR2001PLC033407

Ms. Komal Gupta

Email: [Komal@windlasbiotech.com](mailto:Komal@windlasbiotech.com)

Contact no.: +91 124 2821034



### **Strategic Growth Advisors Pvt. Ltd.**

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Parin Narichania

Email: [jigar.kavaiya@sgapl.net](mailto:jigar.kavaiya@sgapl.net) / [parin.n@sgapl.net](mailto:parin.n@sgapl.net)

Contact no.: +91 9920602034 / +91 9930025733